The food allergy market landscape is advancing through a robust clinical pipeline, with key programs being developed by companies such as DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis ...

The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an ...

Dupilumab treatment was associated with improved bone growth and bone mineral density in children with eczema, according to a study published in the Journal of the American Academy of Dermatology.

Among infants with eosinophilic esophagitis aged younger than 1 year or weighing less than 15 kg, esophageal eosinophilia and ...

Mepolizumab is a monoclonal antibody that targets interleukin-5, a key cytokine in eosinophilic inflammation. The MATINEE ...

USA: Researchers have found in a new study that treatment with abrocitinib enabled more patients with atopic dermatitis to ...

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia Therapeutics and Braveheart Bio the ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Dupilumab's growth is driven by its established market presence, new indications like COPD, broad multi-indication use, and strong clinical performance. Recent approvals and phase III trial successes, ...

Dupixent is already a leading biologic, underpinning sustainable growth. Sanofi and Regeneron Pharmaceuticals reported Dupixent sales of €10.7 billion in 2023, marking a 31% year-over-year increase.

A revolutionary injection for chronic obstructive pulmonary disorder (COPD) is being rolled out on the NHS. The jab tackles the inflammation driving symptoms and could benefit up to 30,000 people with ...

When people have the rare disease eosinophilic gastritis (EoG), many common foods can trigger severe stomach reactions – including dairy, wheat, gluten, egg, soy, fish and nuts. Flare-ups can strike ...